Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.
malignant insulinoma
neuroendocrine tumor
pancreatic neuroendocrine cancer
pasireotide
refractory hypoglycemia
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
01
2022
accepted:
21
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
Identifiants
pubmed: 35518928
doi: 10.3389/fendo.2022.860614
pmc: PMC9063459
doi:
Substances chimiques
Somatostatin
51110-01-1
pasireotide
98H1T17066
Types de publication
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
860614Informations de copyright
Copyright © 2022 Oziel-Taieb, Maniry-Quellier, Chanez, Poizat, Ewald and Niccoli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hormones (Athens). 2016 Apr;15(2):271-276
pubmed: 26732164
Clin Endocrinol (Oxf). 2018 May;88(5):615-624
pubmed: 29205458
Drug Des Devel Ther. 2015 Sep 03;9:5075-86
pubmed: 26366058
J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9
pubmed: 20410233
Ann Oncol. 2017 Jun 1;28(6):1309-1315
pubmed: 28327907
Ann Endocrinol (Paris). 2013 Dec;74(5-6):523-33
pubmed: 23993836
Endocrine. 2020 Nov;70(2):435-438
pubmed: 32621049
Endocr Relat Cancer. 2015 Feb;22(1):1-9
pubmed: 25376618
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Cancer. 2011 Jan 15;117(2):268-75
pubmed: 20824724
Lancet Oncol. 2017 Dec;18(12):1652-1664
pubmed: 29074099
J Endocr Soc. 2020 Nov 05;5(1):bvaa171
pubmed: 33294765
Nat Rev Drug Discov. 2012 Aug;11(8):597-8
pubmed: 22850776